title: Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy.
abstract: OBJECTIVE
  Mesenchymal stromal cells (MSCs) are pluripotent cells that have immunosuppressive and reparative properties in vitro and in vivo. Although autologous bone marrow (BM)-derived MSCs are already clinically tested in transplant recipients, it is unclear whether these BM cells are affected by renal disease. We assessed whether renal failure affected the function and therapeutic potential of BM-MSCs.
  
  
  METHODS
  MSCs from 10 adults with end-stage renal disease (ESRD) and 10 age-matched healthy controls were expanded from BM aspirates and tested for phenotype and functionality in vitro.
  
  
  RESULTS
  MSCs from ESRD patients were >90% positive for CD73, CD90 and CD105 and negative for CD34 and CD45 and showed a similar morphology and differentiation capacity as MSCs from healthy controls. Of importance for their clinical utility, growth characteristics were similar in both groups, and sufficient numbers of MSCs were obtained within 4 weeks. Messenger RNA expression levels of self-renewal genes and factors involved in repair and inflammation were also comparable between both groups. Likewise, microRNA expression profiling showed a broad overlap between ESRD and healthy donor MSCs. ESRD MSCs displayed the same immunosuppressive capacities as healthy control MSCs, demonstrated by a similar dose-dependent inhibition of peripheral blood mononuclear cell proliferation, similar inhibition of proinflammatory cytokines tumor necrosis factor-α and interferon-γ production and a concomitant increase in the production of interleukin-10.
  
  
  CONCLUSIONS
  Expanded BM-MSCs procured from ESRD patients and healthy controls are both phenotypically and functionally similar. These findings are important for the potential autologous clinical application of BM-MSCs in transplant recipients.
authors: Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands. m.e.j.reinders@lumc.nl
authors: Marlies E J
authors: ME
authors: Reinders
authors: Marieke
authors: M
authors: Roemeling-van Rhijn
authors: Meriem
authors: M
authors: Khairoun
authors: Ellen
authors: E
authors: Lievers
authors: Dorottya K
authors: DK
authors: de Vries
authors: Alexander F M
authors: AF
authors: Schaapherder
authors: San W S
authors: SW
authors: Wong
authors: Jaap Jan
authors: JJ
authors: Zwaginga
authors: Jacques M
authors: JM
authors: Duijs
authors: Anton Jan
authors: AJ
authors: van Zonneveld
authors: Martin J
authors: MJ
authors: Hoogduijn
authors: Willem E
authors: WE
authors: Fibbe
authors: Johan W
authors: JW
authors: de Fijter
authors: Cees
authors: C
authors: van Kooten
authors: Ton J
authors: TJ
authors: Rabelink
authors: Helene
authors: H
authors: Roelofs
mesh_terms: D000368:Aged; D001854:Bone Marrow Cells / Q000166:cytology*; D064987:Cell- and Tissue-Based Therapy; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000473:pathology; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000378:metabolism; D008875:Middle Aged; D014182:Transplantation, Autologous